NCT07142798

to Assess the Eradication Rate of 14-day Bismuth/Amoxicillin/PCAB Triple Therapy for the Treatment of Helicobacter Pylori Infection

Efficacy of Bismuth/Amoxicillin/Potassium-competitive Acid Blocker Triple Therapy for the Treatment of Helicobacter Pylori Infection in Taiwan

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Kaohsiung Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To assess the efficacy and safety of 14-day bismuth/amoxicillin/PCAB triple therapy for the treatment of Helicobacter pylori infection in Taiwan

Conditions

• HELICOBACTER PYLORI INFECTIONS

Interventions

Type	Name	Description
DRUG	Bismuth amoxilillin potassium	vonoprazan 20mg， Twice a day amoxicillin 750mg，Four times a day tripotassium dicitrate bismuthate 300mg，Four times a day for 14 days

Timeline

• Start date: 2024-09-26
• Primary completion: 2025-12-31
• Completion: 2026-01-31
• First posted: 2025-08-27
• Last updated: 2025-08-27

Locations

1 site across 1 country: Taiwan